Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Dun

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Andrology|April 26, 2019
Profiling of epididymal small non-protein-coding RNAsB Nixon, G N De Iuliis, M D Dun, et al.
International Journal of Andrology|March 31, 2012
Investigation of the expression and functional significance of the novel mouse sperm protein, a disintegrin and metalloprotease with thrombospondin type 1 motifs number 10 (ADAMTS10)M D Dun, A L Anderson, E G Bromfield, et al.
Leukemia|September 21, 2018
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
Leukemia|August 31, 2017
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Andrology|April 26, 2019
Profiling of epididymal small non-protein-coding RNAsB Nixon, G N De Iuliis, M D Dun, et al.
International Journal of Andrology|March 31, 2012
Investigation of the expression and functional significance of the novel mouse sperm protein, a disintegrin and metalloprotease with thrombospondin type 1 motifs number 10 (ADAMTS10)M D Dun, A L Anderson, E G Bromfield, et al.
Leukemia|September 21, 2018
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
Leukemia|August 31, 2017
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemiaS Degryse, C E de Bock, S Demeyer, et al.
Pageof 1